One Percent Tenofovir Applied Topically to Humanized BLT Mice and Used According to the CAPRISA 004 Experimental Design Demonstrates Partial Protection from Vaginal HIV Infection, Validating the BLT Model for Evaluation of New Microbicide Candidates

Recent iPrEx clinical trial results provided evidence that systemic preexposure prophylaxis (PrEP) with emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF) can partially prevent rectal HIV transmission in humans. Similarly, we have previously demonstrated that systemic administration of the...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Denton, Paul W., Othieno, Florence, Martinez-Torres, Francisco, Zou, Wei, Krisko, John F., Fleming, Elisa, Zein, Sima, Powell, Daniel A., Wahl, Angela, Kwak, Youn Tae, Welch, Brett D., Kay, Michael S., Payne, Deborah A., Gallay, Philippe, Appella, Ettore, Estes, Jacob D., Lu, Min, Garcia, J. Victor
Natura: Artigo
Lingua:Inglês
Pubblicazione: American Society for Microbiology 2011
Soggetti:
Vaccines and Antiviral Agents
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC3147928/
https://ncbi.nlm.nih.gov/pubmed/21593172
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/JVI.00537-11
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi